Getinge AB (publ)

OM:GETI B Stock Report

Market Cap: SEK 49.2b

Getinge Valuation

Is GETI B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GETI B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GETI B (SEK172.65) is trading below our estimate of fair value (SEK391.75)

Significantly Below Fair Value: GETI B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GETI B?

Key metric: As GETI B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GETI B. This is calculated by dividing GETI B's market cap by their current earnings.
What is GETI B's PE Ratio?
PE Ratio27.8x
EarningsSEK 1.69b
Market CapSEK 49.16b

Price to Earnings Ratio vs Peers

How does GETI B's PE Ratio compare to its peers?

The above table shows the PE ratio for GETI B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.9x
EKTA B Elekta
21.2x17.9%SEK 23.9b
ARJO B Arjo
18.3x24.5%SEK 9.3b
CEVI CellaVision
35.7x22.8%SEK 5.6b
ELOS B Elos Medtech
104.3xn/aSEK 5.7b
GETI B Getinge
27.8x22.0%SEK 49.2b

Price-To-Earnings vs Peers: GETI B is good value based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (44.9x).

Price to Earnings Ratio vs Industry

How does GETI B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GETI B 27.8xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GETI B is good value based on its Price-To-Earnings Ratio (27.8x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is GETI B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GETI B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.8x
Fair PE Ratio33.3x

Price-To-Earnings vs Fair Ratio: GETI B is good value based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (33.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GETI B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 172.65
SEK 225.44
+30.6%
16.0%SEK 300.00SEK 180.00n/a9
Nov ’25SEK 186.65
SEK 225.44
+20.8%
16.0%SEK 300.00SEK 180.00n/a9
Oct ’25SEK 218.20
SEK 233.00
+6.8%
14.0%SEK 300.00SEK 190.00n/a8
Sep ’25SEK 213.60
SEK 230.00
+7.7%
14.2%SEK 300.00SEK 190.00n/a8
Aug ’25SEK 202.60
SEK 230.00
+13.5%
14.2%SEK 300.00SEK 190.00n/a8
Jul ’25SEK 181.45
SEK 225.44
+24.2%
15.8%SEK 290.00SEK 165.00n/a9
Jun ’25SEK 187.00
SEK 229.22
+22.6%
13.2%SEK 300.00SEK 186.00n/a9
May ’25SEK 235.00
SEK 235.50
+0.2%
12.2%SEK 300.00SEK 186.00n/a10
Apr ’25SEK 215.40
SEK 226.10
+5.0%
14.9%SEK 300.00SEK 164.00n/a10
Mar ’25SEK 206.90
SEK 227.10
+9.8%
15.2%SEK 300.00SEK 164.00n/a10
Feb ’25SEK 197.00
SEK 236.60
+20.1%
11.3%SEK 300.00SEK 210.00n/a10
Jan ’25SEK 224.30
SEK 228.56
+1.9%
12.8%SEK 300.00SEK 190.00n/a9
Dec ’24SEK 226.70
SEK 220.33
-2.8%
17.4%SEK 300.00SEK 150.00n/a9
Nov ’24SEK 202.50
SEK 210.89
+4.1%
14.7%SEK 250.00SEK 150.00SEK 186.659
Oct ’24SEK 192.70
SEK 203.11
+5.4%
16.1%SEK 250.00SEK 134.00SEK 218.209
Sep ’24SEK 190.60
SEK 203.11
+6.6%
16.1%SEK 250.00SEK 134.00SEK 213.609
Aug ’24SEK 198.70
SEK 203.11
+2.2%
16.1%SEK 250.00SEK 134.00SEK 202.609
Jul ’24SEK 188.95
SEK 230.40
+21.9%
19.9%SEK 300.00SEK 139.00SEK 181.4510
Jun ’24SEK 251.30
SEK 265.30
+5.6%
11.8%SEK 300.00SEK 193.00SEK 187.0010
May ’24SEK 259.90
SEK 260.33
+0.2%
11.6%SEK 295.00SEK 193.00SEK 235.009
Apr ’24SEK 252.70
SEK 252.89
+0.07%
8.6%SEK 285.00SEK 208.00SEK 215.409
Mar ’24SEK 218.30
SEK 253.44
+16.1%
8.1%SEK 285.00SEK 208.00SEK 206.909
Feb ’24SEK 239.40
SEK 252.89
+5.6%
7.9%SEK 285.00SEK 208.00SEK 197.009
Jan ’24SEK 216.30
SEK 264.33
+22.2%
5.5%SEK 285.00SEK 240.00SEK 224.309
Dec ’23SEK 245.50
SEK 274.89
+12.0%
5.4%SEK 300.00SEK 250.00SEK 226.709
Nov ’23SEK 226.80
SEK 273.63
+20.6%
5.5%SEK 300.00SEK 250.00SEK 202.508

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Iconovo

SEK 78.6m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.10

7D

-1.2%

1Y

-46.3%

Dignitana

SEK 92.6m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.10

7D

-4.3%

1Y

-48.6%

Mentice

SEK 544.6m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.00

7D

-16.0%

1Y

-52.3%